Highlights Comera Life Sciences Holdings, Inc.

Equities

CMRA

US20037C1080

Market Closed - OTC Markets Other stock markets 14:14:40 2024-05-30 EDT			5-day change	1st Jan Change
0.0227 ^USD	-0.87%		-22.53%	-58.73%

01-30	Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	CI
01-30	Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $136,310	11-09	MT
Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities	23-08-16	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q2 Revenue $315.1M	23-08-10	MT
Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform	23-08-08	CI
Comera Life Sciences Holdings, Inc. Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients	23-07-20	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q1 Revenue $392.9M	23-05-11	MT
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q4 Revenue $156,120	23-03-16	MT
North American Morning Briefing : Payrolls Shocker, China Spat to Weigh on Stocks	23-02-06	DJ
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $234,922	22-11-10	MT
Comera Life Sciences Holdings, Inc. Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study	22-10-18	CI
Comera Life Sciences Holdings, Inc. Expands Woburn Operations	22-10-04	CI
Comera Life Sciences : Provides Business Highlights and Reports Financial Results for the Second Quarter 2022 - Form 8-K	22-08-15	PU
Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit	22-08-11	CI
Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient	22-07-13	CI
Comera Life Sciences Secures US Patent Related to Its SQore Platform	22-06-22	MT
Comera Life Sciences, Inc. completed the acquisition of OTR Acquisition Corp. from OTR Acquisition Sponsor LLC, Karpus Management Inc, Polar Asset Management Partners Inc., Hudson Bay Capital Management LP and others in a reverse merger transaction.	22-05-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Comera Life Sciences Holdings, Inc.

Equities

CMRA

US20037C1080

Highlights

Filters